נולוג'יקס 250 מ"ג

Land: Israel

Sprache: Hebräisch

Quelle: Ministry of Health

Wirkstoff:

BELATACEPT 25 MG/ML

Verfügbar ab:

BRISTOL-MYERS SQUIBB (ISRAEL) LIMITED

ATC-Code:

L04AA28

Darreichungsform:

POWDER FOR CONCENTRATE FOR INFUSION

Verabreichungsweg:

I.V

Hergestellt von:

BRISTOL-MYERS SQUIBB S.R.L, ITALY

Therapiegruppe:

BELATACEPT

Anwendungsgebiete:

Nulojix, in combination with corticosteroids and mycophenolic acid (MPA), is indicated for prophylaxis of graft rejection in adults receiving a renal transplant. It is recommended to add an interleukin (IL)-2 receptor antagonist for induction therapy to this belatacept-based regimen

Berechtigungsdatum:

2012-08-01